Daily Effort: Pharmacodiligence plus, potential, positive lifespan side effects on drug labels?

Attempting a new post series called Daily Effort: a dense expression of an Open Lifespan/Open Healthspan related idea (question, argument, proposal …) in a couple of sentences. Without context or tight, detailed argumentation. Consider these as drafts, some of them will be elaborated upon, some of them will be revoked if don’t stand up to scrutiny. In any case, these are my drafts here am working on, reaching a stage where it might be interesting for others too. Let’s go.

Today’s idea is simple and I phrase it as a question (and a  bundle of follow-up questions), rather than a proposal as originally intended: if a drug has reported and potential lifespan and/or healthspan lengthening benefits, should this information be printed on the label too amongst potential side effects? Think of metformin here as a prime example where observational evidence suggests longer survival time for metformin user diabetics compared to non-diabetic, non-users. Continue reading “Daily Effort: Pharmacodiligence plus, potential, positive lifespan side effects on drug labels?”